Massive Wave Research is conducting an in-depth market research study with U.S. payers to explore decision-making, care management, and access dynamics surrounding biologic therapies for conditions such as asthma, chronic idiopathic/spontaneous urticaria (CIU/CSU), and IgE-mediated food allergies.

This study aims to uncover how payers approach formulary decisions, negotiate pricing, and manage patient access for biologics and biosimilars. Insights will focus on:

• Pharmacy & Therapeutics (P&T) committee involvement in anti-IgE biologics.
• Coverage and utilization trends for conditions like asthma, CSU, and food allergies.
• Pricing and contracting dynamics, including WAC/ASP levels, rebate structures, PBM spreads, and provider mark-ups.
• Impact of biosimilars on payer strategies and step-edit rules.

We are engaging professionals in roles such as:

• Medical Directors
• Directors of Pharmacy

Why This Matters?

Biologic therapies are transforming treatment landscapes for allergic and immunologic conditions. Understanding payer perspectives is critical for improving access, affordability, and patient outcomes.

Interested in Taking Part?

If you’d like to participate, please complete our short online screening form. This will help us determine your eligibility and allow our team to contact you with next steps.